Compare RDY & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RDY | SF |
|---|---|---|
| Founded | 1984 | 1890 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 12.7B |
| IPO Year | 2001 | N/A |
| Metric | RDY | SF |
|---|---|---|
| Price | $14.72 | $112.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $16.90 | ★ $133.75 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 0.49% | ★ 1.70% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.50 | $16.23 |
| Revenue Next Year | $2.96 | $7.61 |
| P/E Ratio | ★ $18.67 | $20.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.26 | $73.27 |
| 52 Week High | $16.17 | $134.74 |
| Indicator | RDY | SF |
|---|---|---|
| Relative Strength Index (RSI) | 67.64 | 29.36 |
| Support Level | $13.76 | $109.98 |
| Resistance Level | $15.01 | $117.58 |
| Average True Range (ATR) | 0.23 | 4.72 |
| MACD | 0.07 | -1.12 |
| Stochastic Oscillator | 92.73 | 4.06 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from investment banking and trading.